On Friday, Aquestive Therapeutics Inc (NASDAQ: AQST) opened lower -37.04% from the last session, before settling in for the closing price of $6.21. Price fluctuations for AQST have ranged from $2.12 to $7.55 over the past 52 weeks.
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 27.90%. Company’s average yearly earnings per share was noted -21.35% at the time writing. With a float of $114.24 million, this company’s outstanding shares have now reached $121.66 million.
Aquestive Therapeutics Inc (AQST) Insider Activity
A key investor’s attitude towards the stock of the Drug Manufacturers – Specialty & Generic industry is another important factor to consider. The insider ownership of Aquestive Therapeutics Inc is 6.36%, while institutional ownership is 51.22%. The most recent insider transaction that took place on Nov 17 ’25, was worth 286,209. Before that another transaction happened on Oct 15 ’25, when Company’s Chief Operating Officer sold 67,575 for $7.01, making the entire transaction worth $473,701. This insider now owns 240,771 shares in total.
Aquestive Therapeutics Inc (AQST) Earnings and Forecasts
If we go through the results of last quarter, which was made public on 12/31/2024, the company posted -0.16 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at -0.13) by -0.03. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.14 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -21.35% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 23.31% during the next five years compared to 27.90% growth over the previous five years of trading.
Aquestive Therapeutics Inc (NASDAQ: AQST) Trading Performance Indicators
Check out the current performance indicators for Aquestive Therapeutics Inc (AQST). In the past quarter, the stock posted a quick ratio of 5.62. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 17.46.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.70, a number that is poised to hit -0.13 in the next quarter and is forecasted to reach -0.53 in one year’s time.
